Last reviewed · How we verify

NCT06194760

Evaluation of Vitrectomy With ILM Peeling in Myopic Macular Hole With Only Posterior Retinal Detachment

Status unknown NA Last updated 8 January 2024
What this trial tests

NA trial testing Vitrectomy with ILM peeling in Retinal Detachment in 13 participants. Status unknown.

Timeline
1 January 2022
Primary endpoint
1 December 2023
15 January 2024

Quick facts

Lead sponsorAl-Azhar University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment13
Start date1 January 2022
Primary completion1 December 2023
Estimated completion15 January 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Al-Azhar University

Who can join

Adults 15 to 60, any sex, with Retinal Detachment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Retinal detachment (RD) resulting from the macular hole (MH), also known as MH-induced RD (MHRD), most commonly occurs in eyes with high myopia and results in irreversible visual disorders. Although ILM peeling for MHRD reportedly achieves a high retinal reattachment rate that ranges from 70% to 100%, the MH closure rate is relatively low, ranging from 10% to 70%.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Retinal Detachment

Currently open trials in the same condition.

Other Al-Azhar University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06194760.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing